drugset / Trial / NCT07657611
Inhaled mRNA Immunotherapy for Patients With Advanced Lung Cancer or Pulmonary Metastatic Solid Tumors
Phase 0
Not yet recruiting
60 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label phase I master platform study to evaluate the safety, tolerability and preliminary anti-tumor efficacy of multiple inhaled in-vivo mRNA immunotherapies in adult patients with advanced solid tumors. Subjects will receive inhalation mRNA formulations at ascending dose levels following a 3+3 dose-escalation design to determine maximum tolerated dose and recommended phase II dose.
Timeline
- Start
- 2026-06-10
- Primary completion
- 2026-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMD007-T1 | Messenger RNA (mRNA) | 300 ug | Inhaled |
| Subject | BMD013-T3 | Messenger RNA (mRNA) | 300 ug | Inhaled |
| Subject | BMD014-T5 | Messenger RNA (mRNA) | 300 ug | Inhaled |